Adequate pain relief in patients with far advanced cancer sometimes requires intrathecal (IT) administration of a combination of opioids and local anesthetics. Tumor progression as well as the IT administration of local anesthetics can lead to neurologic dysfunction during treatment. Five patients showed symptoms of compression of the cauda equina or spinal cord shortly after the start of combined IT administration of morphine and bupivacaine in a dosage usually not associated with neurologic symptoms. Unexpectedly, neurologic evaluation suggested compression of the cauda equina and spinal cord, which was confirmed radiographically. Manifestation of new neurologic symptoms during low dose bupivacaine infusion intrathecally might therefore be an early indicator of space-occupying processes within the spinal canal in cancer patients.
Introduction
In about 15% of cancer patients, neurologic symptoms can be present during the course of the disease (Posner, 1995) . Compression of the spinal cord or cauda equina manifests clinically in about 5% of cancer patients (Gilbert et al., 1978; Schiff et al., 1995) and is usually accompanied by pain complaints in the back, with or without radiation into an extremity. Frequently, sensory disturbances, motor weakness ultimately leading to paralysis, and problems with fecal and urinary continence can follow if left untreated (Portenoy, 1987) .
In some of these patients, pain relief can either remain inadequate despite the administration of various analgesics including opioids or can be accompanied by intolerable side-effects. Spinal (i.e., epidural, intrathecal (IT)) administration of morphine may then be considered (Krames et al., 1985; Onofrio and Yaksh, 1990) although neurogenic pain components do not always respond favourably (Arnér and Arnér, 1985; Max et al., 1985) . Recently a combination of intrathecally administered morphine and bupivacaine (an amide-type local anesthetic) was proposed as a step forward toward the solution of these intractable pain problems (van Dongen et al., 1993; Sjöberg et al., 1994) . Usually a wide dosage range of IT bupivacaine is tolerated without severe side-effects below a bupivacaine dosage of 45 mg day -1 (Sjöberg et al., 1994) , but individual titration remains mandatory to prevent neurologic dysfunction. We report five cancer patients who developed unexpected, severe, neurologic disturbances during continuous, lowdose, IT morphine/bupivacaine infusions. The clinical signs, differential diagnosis and management are described.
Case histories

Patient no. 1
A 63-year-old man suffered from increasing back pain, radiating into the anterior side of both legs despite high oral morphine (480 mg day -1 ) intake. The pain was related to widespread bone metastases of a prostatic carcinoma. Diffuse vertebral metastases were shown previously on
